Evidence
Surveillance decision
We will not update the guideline on idiopathic pulmonary fibrosis (IPF) at this time.
We will amend the guideline to:
-
Add a cross-reference to NICE technology appraisal guidance on nintedanib for treating idiopathic pulmonary fibrosis, published in January 2016, from recommendations 1.5.11–1.5.15.
Reason for the decision
Assessing the evidence
We found 38 studies through surveillance of this guideline.
We identified evidence that supports current recommendations on:
-
diagnosis – multidisciplinary team
-
information and support
-
management – pulmonary rehabilitation
-
management – disease-modifying pharmacological interventions.
We also found new evidence that was not thought to have an impact on current recommendations, including:
-
management – best supportive care.
We asked topic experts whether this new evidence would affect current recommendations on diagnosis and management of IPF in this guideline. Generally, the topic experts thought that an update was not needed.
We did not find any evidence in areas not covered by the original guideline.
We did not find any evidence related to:
-
awareness of clinical features of IPF
-
prognosis
-
management – ventilation
-
review and follow‑up.
For any new evidence relating to published or ongoing NICE technology appraisals, the guideline surveillance review deferred to the technology appraisal decision. This included nintedanib for treating idiopathic pulmonary fibrosis, published in January 2016.
Overall decision
After considering all the evidence and views of topic experts and stakeholders, we decided that no update is necessary for this guideline.
See how we made the decision for further information.
This page was last updated: